Document:

Exhibit
10.5

 

AGREEMENT
BY AND BETWEEN ZANDER THERAPEUTICS, INC. ("ZANDER") AND ENTEST

BIOMEDICAL,INC.("ENTEST")
dated February 28, 2017 ("Agreement'')

 

WHEREAS
ENTEST paid $1,115 of incorporation expenses incurred in the incorporation of ZANDER on June 18, 2015("lncorporation Expenses")

WHEREAS
ENTEST has issued 8,000,000 common shares of ENTEST to Regen Biopharma, Inc. on September 28, 2015 in satisfaction of $100,000
owed to Regen Biopharma, Inc. by ZANDER ("License Fee")

WHEREAS
the Incorporation Expenses were paid by ENTEST and the License Fee was satisfied by ENTEST in anticipation of the issuance to
ENTEST of the securities of ZANDER

THEREFORE
IT IS AGREED AS FOLLOWS:

 

ZANDER
shall issue Three Million of its Common Shares to ENTEST as consideration for the payment of the Incorporation Expenses and the
satisfaction of the License Fee.

ENTIRE
AGREEMENT. This instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes
any prior agreements of the parties with respect to the subject matter hereof. It may be changed only by an agreement in writing
signed by a party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

GOVERNING
LAW AND VENUE. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient
venue for such proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement,
then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys' fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

 

	Zander Therapeutics, Inc.
	By:	/s/David R. Koos
	 	David R. Koos Chairman and CEO February 28, 2017
	 
	Entest
	By:	/s/David R. Koos
	 	David R. Koos Chairman and CEO February 28, 2017Exhibit
10.6

 

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”),
a _______ whose address is _____________. 

WHEREAS:

The
Purchaser desires to purchase the common stock of the Company (“Shares”) in accordance with the terms and conditions
set forth herein.

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

 

1.
Purchase Price

The
purchase price per Share ( “Purchase Price”), payable in US Dollars, shall be $2.50 per Share.

2.
Form of Payment

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company

 

WIRE
INSTRUCTIONS:

____________

_____________

3.
Issuance of Stock 

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

    	 	1	 

     

    

4.
Purchaser’s Representations and Warranties

(a)
As of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public
sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933,
as amended ( the “Act”).

(b)
The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under
the Act

(c)
The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its advisors.
Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not
disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser. 

    	 	2	 

     

    

(d)
Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(e)
The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Purchaser is a party, or by which Purchaser is or may be bound.

5.
Company’s representations and warranties

(a)
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and
has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b)
The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Company is a party, or by which Company is or may be bound.

6.
Restricted Securities Acknowledgement

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Act , and
shall contain the following restrictive legend:

    	 	3	 

     

    

 

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

7.
Entire Agreement

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

8.
Governing Law, Venue, Waiver Of Jury Trial

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	 	4	 

     

    

IN
WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 10th day of April, 2017.

By:

 

Zander
Therapeutics, Inc.

/s/
David Koos

David
Koos, CEO

	 

         

        Purchaser

	 
	__________
	 
	 
	Number
    of Shares of Common Stock purchased	8,000
	Total
    Purchase Price:	$20,000Exhibit
10.7

  

 

 

SECURITIES
PURCHASE AGREEMENT

THIS
SECURITIES PURCHASE AGREEMENT (the ''Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the (“Company'') whose address is

Brian
Devine (

Person
whose address is _____________

WHEREAS:

The
Purchaser desires to purchase shares of the common stock of the Company ('Shares'') in

accordance
with the terms and conditions set forth herein.

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and

conditions
set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

		1.	Purchase
                                         Price

The
purchase price per Share ("Purchase Price"), payable in US Dollars, shall be $1
per Share.

		2.	Form
                                         of Payment

The
Purchaser shall pay the Purchase Prjce per Share multiplied by that number of Shares 

Purchased
by wire transfer of immediately available funds to the Company on or prior to 6/23/2017

 

WIRE
INSTRUCTIONS:

Zander
Therapeutics Wire Instructions:

 

    	 	1	 

     

    

 

		3.	Issuance
                                         of Stock

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue

to
the Purchaser that number of Shares purchased

		4.	Purchaser's
                                         Representations and Warranties

		(a)	As
                                         of the date
                                         hereto the Purchaser
                                         is purchasing the Shares for its own account and not with a present view towards the
                                         public sale or distribution thereof, except pursuant to sales registered or exempted
                                         from registration under the Securities Act of 1933, as amended (the ''Act'').

		(b)	The
                                         Purchaser is an "accredited investor', as that term is defined in Rule 501(a) of

Regulation
D promulgated under the Act

		(c)	The
                                         Purchaser and its
                                         advisors, if any, have been furnished with all
                                         materials relating to the business, finances and operations of the Company and materials
                                         relating to the offer and sale of the Stocks which
                                         have been requested by the
                                         Purchaser or its advisors. Notwithstanding the
                                         foregoing, the Company has not disclosed to the
                                         Purchaser any material nonpublic information and will not disclose such information unless
                                         such information is disclosed to the public prior to such disclosure to the Purchaser.

		(d)	Purchaser
                                         has the requisite power and authority
                                         to enter into
                                         and perform its obligations under this Agreement
                                         without the consent, approval or authorization ot or obligation to notify, any person,
                                         entity or governmental agency which consent has not been obtained.

		(e)	The
                                         execution delivery
                                         and performance of this Agreement by Purchaser
                                         does not and shall not constitute Purchaser's breach of any statute or regulation or
                                         ordinance of any governmental authority, and shall not conflict with or result in a breach
                                         of or default under any of the terms, conditions, or provisions of any order,
                                         writ, injunctiot1t decree, contract, agreement, or instrument
                                         to which the Purchaser is a party, or by which
                                         Purchaser is or may be bound.

5.
Company's representations and warranties

(a) 
Company is a
corporation duly organized, validly existing and in good standing under the laws of the
state its incorporation and has the requisite corporate power and authority
to enter into and perform its obligations under this Agreement without the consent
approval or authorization of or obligation to notify  any person,
entity or governmental agency which consent has not been obtained.

(b)  
The execution, delivery and performance of this
Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any governmental
authority, and shall not conflict with or result in a breach of or default under

    	 	2	 

     

    

 

any
of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the
Company is a partyt  Ot" by which Company is or may be bound.

6.
Restricted Securities  Acknowledgement

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 sha11 constitute "restricted securities" as that term is defined in Rule 144 promulgated under the
Act, and shall contain the following restrictive legend:

'"IHESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIESACT OF 1933, AS AMENDED (THE "ACT''), OR SECURITIES LAws OF ANY STATE
AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE-OF AN EFEBCTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."

7.
Entire Agreement

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

8.
Governing Law, Venue, Waiver Of Jury Trial

All
 questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys' fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the parties have hereunto  executed this Agreement on the 20th Day of June 2017

 

Zander
Therapeutics, Inc

/s/David
Koos

David
Koos , CEO

6.20.2017

 

Purchaser

By:/s/Brian
Devine

6/20/2017

Number
of Shares of Common Stock Purchased $100,000

Total
Purchase Price: $100,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]